Bile acid receptor
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
<StructureSection load='3ruu' size='350' side='right' caption='Structure of human FXR ligand-binding domain (grey) complex with non-steroidal agonist, nuclear receptor coactivator 1 peptide (green) and sulfate ions (PDB entry [[3ruu]])' scene=''> | <StructureSection load='3ruu' size='350' side='right' caption='Structure of human FXR ligand-binding domain (grey) complex with non-steroidal agonist, nuclear receptor coactivator 1 peptide (green) and sulfate ions (PDB entry [[3ruu]])' scene=''> | ||
| + | == Function == | ||
'''Bile acid receptor or farnesoid X receptor''' (FXR) binds bile acids, then translocates to the nucleus, forms a dimer and binds to hormone response elements. This causes up- or down-regulation of certain genes involved in cholesterol metabolism, lipid homeostasis and absorption of fats and vitamins. FXR ligand-binding domain (LBD) binds chenodeoxycholic acid (CDC), lithocholic acid and deoxycholic acid. | '''Bile acid receptor or farnesoid X receptor''' (FXR) binds bile acids, then translocates to the nucleus, forms a dimer and binds to hormone response elements. This causes up- or down-regulation of certain genes involved in cholesterol metabolism, lipid homeostasis and absorption of fats and vitamins. FXR ligand-binding domain (LBD) binds chenodeoxycholic acid (CDC), lithocholic acid and deoxycholic acid. | ||
| + | |||
| + | == Disease == | ||
| + | |||
| + | FXR is involved in pathophysiology of inflammatory bowel disease, colorectal cancer and type II diabetes. | ||
| + | |||
| + | == Relevance == | ||
| + | |||
| + | FXR and other bile acid receptors are targets for the treatment of dyslipidemia, diabetes and cardiovascular disease. | ||
==3D structures of bile acid receptor== | ==3D structures of bile acid receptor== | ||
Revision as of 09:04, 11 November 2015
| |||||||||||
